Andrea Fülöp

17.6k total citations · 3 hit papers
14 papers, 9.2k citations indexed

About

Andrea Fülöp is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Andrea Fülöp has authored 14 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 1 paper in Surgery. Recurrent topics in Andrea Fülöp's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Andrea Fülöp is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Andrea Fülöp collaborates with scholars based in Hungary, Spain and United States. Andrea Fülöp's co-authors include Ali Tafreshi, Sinéad Cuffe, Rina Hui, Suman Rao, Andrew Robinson, Nir Peled, Katsuyuki Hotta, Delvys Rodríguez‐Abreu, Julie R. Brahmer and Maya Gottfried and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Andrea Fülöp

13 papers receiving 9.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2016 7.1k citations Martin Reck, Delvys Rodríguez‐Abreu et al. New England Journal of Medicine profile →
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

2019 1.1k citations Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology profile →
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

2021 616 citations Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Andrea Fülöp

Since Specialization

Citations

This map shows the geographic impact of Andrea Fülöp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Fülöp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Fülöp more than expected).

Fields of papers citing papers by Andrea Fülöp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Fülöp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Fülöp. The network helps show where Andrea Fülöp may publish in the future.

Co-authorship network of co-authors of Andrea Fülöp

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Fülöp. A scholar is included among the top collaborators of Andrea Fülöp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Fülöp. Andrea Fülöp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Machine Learning-enhanced X-ray-based Radiomics in the Identification of Post-COVID Patients 2024 ·Archivos de Bronconeumología ·Andrea Fülöp, Jeovanis Gil, Anita Rózsás, (unknown), (unknown), (unknown), Judit Berta, Péter Döme, György Marko‐Varga, Balázs Döme, Anna Kerpel-Fronius, Zsolt Megyesfalvi	0
2	Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC. 2023 ·Journal of Clinical Oncology ·Sophie Cousin, Luis Paz‐Ares, Andrea Fülöp, Ildikó Horváth, (unknown), Jon Zugazagoitia, Laura Bonanno, José Antonio López-Vilariño, Carmen Kahatt, (unknown), Javier Gómez, Ali Zeaiter, Alejandro Navarro, Kostas Syrigos, Egbert F. Smit, Tudor–Eliade Ciuleanu, Alberto Chiappori, Rafael López‐López, Benjamin Besse	1
3	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% breakdown → 2021 ·Journal of Clinical Oncology ·Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Ticiana Leal, Jonathan W. Riess, Erin Jensen, Bin Zhao, M. Catherine Pietanza, Julie R. Brahmer	616
4	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater breakdown → 2019 ·Journal of Clinical Oncology ·Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, (unknown), Suman Rao, Katsuyuki Hotta, Kristel Vandormael, Antonio Riccio, Jing Yang, M. Catherine Pietanza, Julie R. Brahmer	1121
5	A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy. 2018 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Igor Bondarenko, Tudor–Eliade Ciuleanu, Maciej Bryl, Andrea Fülöp, David Vicente, Helge Bischoff, Karla Hurt, Yi Lu, Shawn T. Estrem, Sameera R. Wijayawardana, Alan Y. Chiang, Ramaswamy Govindan	8
6	Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). 2018 ·Journal of Clinical Oncology ·Luis Paz‐Ares, Alexander Luft, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Shunichi Sugawara, Ying Cheng, Silvia Novello, Balázs Halmos, Yue Shentu, Dariusz M. Kowalski	84
7	ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy. 2018 ·Journal of Clinical Oncology ·Anna F. Farago, Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Andrea Fülöp, Alejandro Navarro, Laura Bonanno, José Antonio López-Vilariño, Rafael N. Nuñez, Carmen Kahatt, (unknown), Arturo Soto-Matos	3
8	PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024 2017 ·Journal of Thoracic Oncology ·Julie R. Brahmer, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Anne C. Deitz, Gregory M. Lubiniecki, Jin Zhang, Reshma Rangwala, Martin Reck	10
9	P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC) 2017 ·Journal of Thoracic Oncology ·Edward B. Garon, Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, David C. Turner, Julie A. Stone, Reshma Rangwala, Julie R. Brahmer	1
10	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial 2017 ·The Lancet Oncology ·Julie R. Brahmer, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Jin Zhang, Gregory M. Lubiniecki, Anne C. Deitz, Reshma Rangwala, Martin Reck	255
11	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy 2017 ·Clinical Lung Cancer ·Enriqueta Felip, Vera Hirsh, Sanjay Popat, Manuel Cobo, Andrea Fülöp, C. Dayen, José Trigo, Richard Gregg, Cornelius F. Waller, Jean‐Charles Soria, Glenwood Goss, J Gordon, Bushi Wang, Michael Palmer, E. Ehrnrooth, Shirish M. Gadgeel	25
12	Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. 2017 ·Journal of Clinical Oncology ·Julie R. Brahmer, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, (unknown), Yue Shentu, Reshma Rangwala, Martin Reck	42
13	Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer breakdown → 2016 ·New England Journal of Medicine ·Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer	7054
14	Transbronchial Needle Aspiration of Hilar and Mediastinal Lymph Nodes: 2004 ·Journal of Bronchology ·(unknown), Katalin Udud, (unknown), Andrea Fülöp, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact